Tirzepatide

Overview

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Built on a modified GIP peptide backbone with engineered GLP-1 receptor cross-reactivity, it represents a novel approach to incretin-based research by simultaneously activating two complementary metabolic pathways.

The peptide's dual agonism is achieved through careful sequence engineering that preserves the native GIP receptor binding while incorporating structural elements that confer GLP-1 receptor affinity. A C₂₀ fatty diacid moiety provides albumin binding for extended duration of action.

Clinical trial programs (SURPASS, SURMOUNT) have demonstrated unprecedented efficacy in both glycemic control and weight reduction, establishing Tirzepatide as a landmark in incretin pharmacology research.

Chemical Profile

Mechanism of Action

Tirzepatide's dual mechanism involves simultaneous activation of both GIP receptors (GIPR) and GLP-1 receptors (GLP-1R). At GIPR (expressed on pancreatic beta cells, adipocytes, and brain), activation enhances glucose-dependent insulin secretion and may improve adipocyte function and lipid metabolism. At GLP-1R, activation promotes insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite through central pathways.

The synergistic effect of dual agonism produces greater metabolic benefits than either pathway alone. GIP receptor activation in adipose tissue may enhance lipid storage capacity and improve adipocyte insulin sensitivity, while GLP-1R activation in the hypothalamus suppresses appetite. The combined effect addresses multiple aspects of metabolic dysfunction simultaneously.

Research Applications

• Dual incretin receptor pharmacology
• Glucose-dependent insulinotropic effects
• Weight management and body composition
• Type 2 diabetes research models
• Cardiovascular risk reduction
• Adipose tissue biology and lipid metabolism
• Comparative incretin receptor studies

Handling & Reconstitution

1. 1Allow the vial and sterile water to reach room temperature (15–25°C).
2. 2Using a sterile syringe, withdraw the appropriate volume of sterile water.
3. 3Inject the water slowly along the inside wall of the vial — do not spray directly onto the powder.
4. 4Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously.
5. 5Once reconstituted, store at 2°C – 8°C. Protect from light.
6. 6Use within 28 days after reconstitution.
7. 7Do not freeze reconstituted solution.